AR and Familial prostate cancer: demonstrated that inhibitor of nuclear factor kappa B kinase epsilon (IKBKE) could not only affect AR transcriptional levels through YAP but also regulate AR transcriptional activity, and proposed a regulatory strategy involving IKBKE-YAP-AR in prostate cancer (69).